Regulatory · Reviewed 2026-06-04
503A vs 503B Semaglutide Pharmacies
The two compounding pathways follow different rules. Knowing which one a program uses tells you a lot about its legal footing in 2026.
Quick Answer
A 503A pharmacy compounds for a specific patient under an individual prescription, under a long-standing framework that does not depend on the shortage list. A 503B outsourcing facility compounds larger batches and is the focus of the FDA's 2026 bulks-list proposal. The distinction affects both legality and where your medication comes from.
| Feature | 503A pharmacy | 503B outsourcing facility |
|---|---|---|
| Basis | Individual patient prescription | Bulk compounding under 503B conditions |
| Scale | Patient-specific | Larger batches |
| 2026 bulks-list proposal | Not the direct subject | Directly affected if finalized |
| Shortage dependence | Operates separately from shortage status | Historically relied on bulks list or shortage status |
Key Facts
- 503A = patient-specific; 503B = outsourcing-facility scale.
- The 2026 proposal targets the 503B bulks list for semaglutide.
- Both should use named, state-licensed facilities and the FDA-recognized active form (semaglutide base, not an unapproved salt).
What to Verify
- Whether your program's pharmacy is named and identifiable as 503A or 503B.
- That it is state-licensed.
- That the active form is semaglutide base.
Bottom Line
Ask any provider which pharmacy fills your prescription and whether it is 503A or 503B. The answer affects both legality under the 2026 rules and product provenance.
Compounded semaglutide is not FDA-approved as a finished drug product. Compounded medications may be prescribed only when clinically appropriate and must be evaluated by a licensed prescriber. Branded medications such as Wegovy and Ozempic are FDA-approved products; compounded semaglutide is different and should not be described as FDA-approved, “generic Wegovy,” or “generic Ozempic.”